Hemophagocytic lymphohistiocytosis
Conditions
Interventions
Experimental Group:Jaktinib plus dexamethasone
Sponsors
The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria of HLH-2004; 2. Age >=18 years old; 3. Has not received any HLH treatment regimens containing etoposide; 4. Understand this research and sign the informed consent form; 5. Men, women of childbearing age (postmenopausal women who have been menopausal for at least 12 months or more are considered infertile) and their partners voluntarily take contraceptive measures deemed effective by the researchers during the treatment period and for at least three months after the last use of the study drug; 6. Expected survival period > 2 weeks;
Exclusion criteria
Exclusion criteria: 1.Central nervous system involvement; 2.Known HIV infection; 3.Individuals with severe renal dysfunction (glomerular filtration rate 20); 5.Individuals who have suffered from malignant tumors within the past five years (excluding cured skin basal cell carcinoma and cervical carcinoma in situ); 6.Pregnant or lactating women; 7.Failure to understand or comply with the research protocol; 8.Combining other serious diseases, researchers believe may affect patient safety or compliance. 9.Previous use of or current treatment with JAK inhibitors for HLH; 10.Suspected allergic reaction to study drug; 11.Patients who are taking other investigational drugs or participating in other clinical studies;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety;Overall survival rate within 2 month; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Response rate;Time to Response;HLH-related indicator trends; | — |
Countries
China
Contacts
Public ContactJin Jie
The First Affiliated Hospital of Zhejiang University School of Medicine
Outcome results
None listed